Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
ZEFAZONE (cefmetazole sodium) is a second-generation cephalosporin antibiotic administered by injection used for surgical prophylaxis and treatment of bacterial infections. It functions as a beta-lactam antibiotic that inhibits bacterial cell wall synthesis. This injectable agent has been a mainstay in perioperative antimicrobial stewardship since its 1989 approval.
As a mature injectable antibiotic nearing loss of exclusivity with moderate competitive pressure (30/100), commercial teams are likely optimizing manufacturing efficiency and managing market consolidation rather than driving growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ZEFAZONE offers limited growth trajectory but provides valuable expertise in managing mature injectable products and navigating hospital formulary dynamics. Roles tend to emphasize operational excellence, cost management, and institutional relationships rather than field-based launch activities.
Worked on ZEFAZONE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.